Proposed is a novel quinizarin derivative, and the novel quinizarin derivative has the abilities to inhibit a BET protein, and thus can be used as a pharmaceutical composition for the prevention or treatment of BET protein-related diseases, such as cancer, autoimmune or inflammatory diseases, metabolic diseases, and viral diseases. Particularly, the novel quinizarin derivative has the abilities to inhibit lipogenesis and the expression of liposynthetic factors, and thus can be used as a pharmaceutical composition for the treatment of non-alcoholic fatty liver.
C07C 49/83 - Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups polycyclic
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
C07D 305/08 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
C07D 319/14 - 1,4-DioxanesHydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
2.
NOVEL BENZOTHIOPHENE DERIVATIVE INHIBITING BET PROTEIN AND COMPOSITION FOR TREATMENT OF CANCER, USING SAME
The present invention relates to a novel benzothiophene derivative exhibiting inhibitory activity against a bromodomain and extra-terminal (BET) protein, and a composition for prevention or treatment of cancer, comprising same as an active ingredient.
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/4436 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
3.
COMPOSITION COMPRISING QUINAZOLINE SALT COMPOUND FOR TREATMENT OF ARTHRITIS AND PREPARATION METHOD THEREFOR
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61K 9/00 - Medicinal preparations characterised by special physical form
4.
NOVEL BENZOTHIOPHENE DERIVATIVE AND USE THEREOF AS BET INHIBITOR
The present invention relates to a novel benzothiophene derivative and use thereof as a bromodomain extra-terminal (BET) inhibitor, and, more specifically, to a novel benzothiophene derivative compound of the following chemical formula 1 having inhibitory activity against a BET protein, and a pharmaceutical composition comprising same for preventing or treating BET protein-associated diseases.
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/4436 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
The present application relates to a novel quinizarine derivative, wherein the quinizarine derivative has a bromodomain extra-terminal (BET) protein inhibition ability, and thus can be used in a pharmaceutical composition for preventing or treating cancer, autoimmune or inflammatory diseases, metabolic diseases, viral diseases and the like, which are BET protein-associated diseases. Particularly, the novel quinizarine derivative according to the present application has the ability to inhibit lipogenesis and inhibit the expression of lipogenic factors, and thus can be used in a pharmaceutical composition for treating non-alcoholic fatty liver disease.
C07C 50/34 - Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having three rings
C07C 46/10 - SeparationPurificationStabilisationUse of additives
C07D 305/08 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
C07D 319/22 - 1,4-DioxanesHydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one naphthalene or hydrogenated naphthalene ring system
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
6.
Novel Quercetin Redox Derivative And Use Thereof As BET Inhibitor
The present invention relates to a novel quercetin derivative compound and to a use thereof. More specifically, the present invention relates to a novel quercetin derivative compound having inhibitory activity against bromodomain extra-terminal (BET) proteins, and to a pharmaceutical composition for preventing or treating BET protein-related diseases, comprising the same.
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
7.
NOVEL PEPTIDE INHIBITING BET PROTEIN AND COMPOSITION COMPRISING SAME FOR PROPHYLAXIS AND TREATMENT OF EYE DISEASE
The present invention relates to a novel peptide and a pharmaceutical composition comprising, as an active ingredient, a composition of the peptide for prophylaxis and treatment of various eye diseases including glaucoma, uveitis, wet and dry macular degeneration, age-related macular degeneration, and the like. As the novel peptide according to the present invention inhibits BET protein to ameliorate inflammation caused by retinal damage resulting from epigenetic changes, effects of the peptide on the prophylaxis and amelioration of various eye diseases caused by retinal degeneration have been confirmed. Accordingly, a composition comprising the peptide as an active ingredient may be provided as a pharmaceutical composition for the prophylaxis and treatment of various eye diseases including glaucoma, uveitis, wet and dry macular degeneration, age-related macular degeneration, and the like.
The present invention relates to a novel quercetin derivative compound and to a use thereof. More specifically, the present invention relates to a novel quercetin derivative compound having inhibitory activity against bromodomain extra-terminal (BET) proteins, and to a pharmaceutical composition for preventing or treating BET protein-related diseases, comprising same.
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61P 37/00 - Drugs for immunological or allergic disorders
The present invention relates to a novel quinazoline derivative compound and a use thereof and, more specifically, to a novel quinazoline derivative compound of the following chemical formula 1 having inhibitory activity against a bromodomain extra-terminal (BET) protein, and a pharmaceutical composition for preventing or treating BET protein-related diseases comprising same.
patents
